Clonal evolution and progression

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Aktas Samur A, Corre J, Talluri S, …, Szalat R, …, Samur MK

Journal of Clinical Oncology44(4):321-334DOI: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaPubMed: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Muchtar E, Wisniowski B, Geyer S, …, Szalat R, …, Gertz MA

JAMA Oncology10(10):1362DOI: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisPubMed: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises

Samur MK, Szalat R, Munshi NC

BloodDOI: Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and PromisesPubMed: Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V

American Journal of Hematology97(1):79-89DOI: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumabPubMed: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura F, Bolli N, Angelopoulos N, …, Szalat R, …, Campbell PJ

Nature Communications10(1)DOI: Genomic landscape and chronological reconstruction of driver events in multiple myelomaPubMed: Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Genomic patterns of progression in smoldering multiple myeloma

Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

Nature Communications9(1)DOI: Genomic patterns of progression in smoldering multiple myelomaPubMed: Genomic patterns of progression in smoldering multiple myeloma

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Szalat RE, Talluri S, Royer CM, Wong S, Morgan G, Sanchorawala V, Samur MK, Munshi NC

Blood142(Supplement 1):3416-3416DOI: Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Muchtar E, Palladini G, Schonland S, …, Szalat RE, …, Gertz MA

Blood142(Supplement 1):3411-3411DOI: Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

Blood138(Supplement 1):545-545DOI: Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz M

Clinical Lymphoma Myeloma and Leukemia21:S23-S24DOI: OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma

Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

Clinical Lymphoma Myeloma and Leukemia21:S28DOI: OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Shah P, Aktas-Samur A, Fulciniti M, Szalat R, …, Samur MK

Blood138(Supplement 1):461-461DOI: Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Prabhala R, Samur MK, Talluri S, …, Szalat R, …, Munshi NC

Blood134(Supplement_1):1784-1784DOI: Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

Aktas Samur A, Minvielle S, Fulciniti M, Szalat R, …, Samur M

HemaSphere3(S1):12DOI: S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

The chronological order of copy number changes in hyperdiploid multiple myeloma patients

Maura F, Bolli N, Dawson K, Angelopoulos N, Szalat R, Martincorena I, et al.

HEMASPHERE2(S1):727-727

Bone marrow microenvironment induces genomic instability and enables clonal evolution in multiple myeloma

Perini T, Szalat R, Fulciniti M, Samur MK, Lopez MA, Nanjappa P, Wen K, et al.

Blood130:4408

Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern

Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

Blood128(22):2088-2088DOI: Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern